New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform

...nothing to reform our broken system by emphasizing prevention and public health, then we will have failed. And we do not intend to fail," said Senator tom Harkin (D-IA). "We know that prevention and wellness efforts are a key to reducing costs within a reformed health care system. And they will be a cent...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

... Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503 US Analyst/ Investor enquiries: tom Curry (215) 751 5419 Jen Hill Baxter (215) 751 7002 Cautionary statement regarding forward-lo...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503 US Analyst/ Investor enquiries: tom Curry (215) 751 5419 Jen Baxter (215) 751 7702 Cautionary statement regarding forward-...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503 US Analyst/ Investor tom Curry (215) 751 5419 enquiries: Jen Hill Baxter (215) 751 7002 Genmab Enquiries: Director, In...

Spherix Elects New Independent Director, and Elects Chairman of the Board

...ing his retirement from Kraft Foods International, after having served in two Vice President positions. "We are very pleased with the election of tom Peter to our Board of Directors and are confident that his particular background will be extremely helpful as we prepare for the potential commerciali...

Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples

...imacy . New York: Kensington. (6) Erectile Dysfunction, http://kidney.niddk.nih.gov/kudiseases/pubs/impotence/ . Data accessed 09/28/07. (7) Lue, tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813. (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) ...

invivodata Certified to Deliver EXACT in COPD Trials

...obal customers a reliable and efficient means of implementing the EXACT in their clinical trials as they develop more effective COPD treatments," said tom Henson, invivodata vice president of marketing. COPD, which includes chronic bronchitis and emphysema, is a disease characterized by obstructio...

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds

...curities and Exchange Commission on March 31, 2009. For more information NovaBay Pharmaceuticals, Inc. Chief Financial Officer: tom Paulson, 510-899-8809 tpaulson@novabaypharma.com Invigorate Communications Investor Relations: Gregory Gin, 908-376-7737 ggin@...

Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses

...ts. To learn more about OHH please visit www.oakwood.org . To learn more about Absolute Imaging, LLC please visit www.a3di.com or contact tom Huntley, VP of Sales, at 248-579-0600 / thuntley@a3di.com " target="_new"> thuntley@a3di.com . Absolute Imaging, LLC, is located in Livonia, Michi...

U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent

...e solution and ultimately the gold standard for the treatment of PAD, a serious condition for millions of Americans and others around the world," said tom Tully, Chairman and CEO of IDEV Technologies. "We are excited to begin enrolling subjects into the SUPERB trial and look forward to compiling data tha...

BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference

...rp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, tom Wegman, will present a corporate overview at the upcoming Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009, at 9:30am E...

Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV

... Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503 US Analyst/ Investor enquiries: tom Curry (215) 751 5419 Jen Hill (215) 751 7002 ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... +44 20 8047 5503 US Analyst/ Investor enquiries: Jen Hill +1 215 751 7002 tom Curry +1 215 751 5419 Genmab enquiries: Helle Husted, Sr. Director, Investor Relations T:...

Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy

...n Gaitens (919) 483 2839 Holly Russell (919) 483 2839 GSK US Analyst/ Investor inquiries: tom Curry (215) 751 5419 Valeant Media and Investor inquiries: Laurie W. Little (949) 461 6002 GSK cautionary statement regarding...

Elsevier is Expanding eClinical Solutions in Europe

...eans of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). tom Reller Director of Corp. Relations, Elsevier +1-212-462-1912 T.Reller@Elsevier.com ...

GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition

... Mary Anne Rhyne (919) 483 2839 Jeff McLaughlin (215) 751 7709 US Analyst/ Investor enquiries: tom Curry (215) 751 5419 Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securit...

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

... "LFA-1 antagonists mediate both migration and adhesion of the white blood cells to sites of inflammation as part of the body's immune response," said tom Gadek, Ph.D., chief executive officer of SARcode Corporation. "Lead indications for LFA-1 include dry eye and allergic conjunctivitis, both large indi...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

... Frank Murdolo | +1(215)751-7002 | ------------------------------------------------------------------------- | | tom Curry | +1(215)751-5419 | ------------------------------------------------------------------------- Genmab(R); the Y-shaped Genmab logo(R...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...dical Investors, Silicon Valley Bank Capital, and Genzyme Corporation. For additional information, please contact us. For information please contact tom Mathers at (617) 715-8000 or tom.mathers@peptimmune.com. ...

Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research

...ladelphia, Children's Hospital of Pittsburgh and Children's Memorial Hospital in Chicago are participating in the planning study, which will be led by tom Curran, PhD, Deputy Scientific Director, and Children's Hospital of Philadelphia. According to Dr. Curran, although pediatric brain tumors can be de...

GSK Update on FDA Review of Promacta(R) (Eltrombopag)

... Gwenan White 44 20 8047 5502 US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002 tom Curry 1 215 751 5419 UK Analyst/Investor inquiries: David Mawdsley 44 20 8047 5564 Sally Fe...

The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards

...ted directors Steven Ascher and Jeanne Jordan, Richard Ingham and Pia Ohlin of Agence France-Presse (AFP), Howard Bell of Minnesota Medicine Magazine, tom Walsh of The Ellsworth American, and Terri Peterson Smith of Science and Technology Magazine. The judging panel was composed of both members of the me...

JDSU WaveReady Receives Brocade Data Center Ready Status for Brocade-Based Storage Area Network (SAN) Infrastructures

...We are pleased that JDSU has successfully completed the Data Center Ready testing with Brocade fabric switches in multi-vendor SAN environments," said tom Buiocchi, Brocade Vice President of Worldwide Marketing. "Storage area networks are being deployed worldwide at a rapid rate as a scalable, high perfo...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... David Mawdsley 44 20 8047 5564 US Analyst/ Investor Frank Murdolo 1 215 751 7002 inquiries: tom Curry 1 215 751 5419 References: (1) Herrstedt J, Grunberg SM. Final Poster for Abstract #9549 - Phase III Results for the Novel Neur...

Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

...sley 44 20 8047 5564 US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002 tom Curry 1 215 751 5419 Synta Pharmaceuticals Corp. Inquiries: US Media/Investor inquiries: Rob Kloppenburg ...

GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)

...ary Davies +44 20 8047 5503 US Analyst/Investor enquiries: Frank Murdolo +1 215 751 7002 tom Curry +1 215 751 5419 References 1. O'Shaughnessy J, et. al. Final presentation for abstract #1015 - A randomized study of lapat...

TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial

... Gary Davies +44 20 8047 5503 US Analyst/ Investor enquiries: Frank Murdolo +1 215 751 7002 tom Curry +1 215 751 5419 REFERENCES (1) Baselga J, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive earl...

GlaxoSmithKline Reports Further Progress of Oncology Portfolio

... Gary Davies (020) 8047 5503 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 tom Curry (215) 751 5419 For on-site contact at ASCO 30 May - 3 June 2008: U.S. media only: Sarah Alspach - TYKERB, ARMALA & elesc...

The Yolanda Adams Morning Show and Radio One Gospel Stations Raise More Than $1 Million During National Radiothon Benefiting St. Jude

...cans and Reach Media, Inc. (http://www.blackamericaweb.com ), owner of the tom Joyner Morning Show and other businesses associated with tom Joyner. ...

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years

... Sally Ferguson +44 20 8047 5543 US Analyst/Investor Inquiries: Frank Murdolo (215) 751 7002 tom Curry (215) 751 5419 References: (1) Harper D, Gall S, et al. HPV-007 Efficacy Abstract. "Sustained Immunogenicity and high effica...

Genzyme Announces Presentation of New Positive Data on Carticel(R)

...e study conducted at the Brigham and Women's Hospital in Boston, Mass., Dr. tom Minas reported the findings of a study that compared the results of ACI fol...atment with ACI, effectively limiting their future treatment options," said tom Minas, MD, an internationally renowned orthopaedic surgeon for his extensiv...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

... Gwenan White (020) 8047 5502 US Analyst/Investor inquiries: Frank Murdolo 1 215 751 7002 tom Curry 1 215 751 5419 European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564 ...

Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine

...n supplies the latest in independent market research for the life sciences and a full range of custom research services. For more information, contact tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com . ...

Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information

...ug development market. "Both CW and NEIRB are winning franchises in the healthcare market and both have high caliber management and employees," said tom O'Connor, the Berkery Noyes Managing Director who managed the transaction on behalf of The Thomson Corporation. "Within Jobson Medical Information por...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

... US Media inquiries: Jeff McLaughlin 919-483-2839 Mary Anne Rhyne 919-483-2839 US Analyst/Investor inquiries: Frank Murdolo 215-751-7002 tom Curry 215-751-5419 REFERENCES (1) Bussel, JB., Cheng, G., et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects...

New Data Published in The Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types

...es Alice Hunt +44 20 8047 5502 US Analyst/Investor Inquiries Frank Murdolo +1 215 751 7002 tom Curry +1 215 751 5419 References: 1. Vesikari T., et al, Human rotavirus vaccine is highly efficacious against rotavirus gastroenterit...

New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns

...pheral Perfusion Index as a Possible Tool for Screening for Critical Left Heart Obstruction. Acta Paediatrica 2007;96:1455-1459. Contact: tom McCall Masimo Corporation 949-297-7075 Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad-57, APOD, Improving Outcomes and Reducing...

Male Birth Control Pill, Blackberry Extract for Gingivitis, Skin Cancer and Digestive Health Top List of New Medical Discoveries

... Meeting and Exposition are available upon request. To register for the meeting or to set up an interview with a pharmaceutical expert, please contact tom Huddleston, AAPS at (703) 248-4744 prior to the meeting, HuddlestonT@aaps.org , or Amanda Rich, at (305) 573-9955, arich@golinharris.com . Registrat...

Concentra Offers Flu Vaccines to Keep America Working

...oised to meet the needs of people across the country by providing flu shots when they need them, delivering the right care at the right time," said W. tom Fogarty, M.D., Concentra's Chief Medical Officer. Each year 1 in 5 people become sick with influenza. According to the Centers for Disease Control, o...

GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer

... David Mawdsley +44 20 8047 5564 US Analyst/ Investor Frank Murdolo +1 215 751 7002 enquiries: tom Curry +1 215 751 5419 References: 1. O'Brien M, Ciuleanu TE, Tsekov H, et al. Phase III Trial Comparing Supportive Care Alone With ...